New analysis proposes Severe COVID-19 is a Microvascular Disease
The range of clinical responses to SARS-CoV-2 infection is extremely broad, a factor making the disease particularly difficult to properly
Read moreThe range of clinical responses to SARS-CoV-2 infection is extremely broad, a factor making the disease particularly difficult to properly
Read moreNucleai and Merck KGaA will collaborate utilizing Nucleai’s AI-powered platform to develop pathology-based biomarkers as companion diagnostics. Nucleai, a precision
Read moreThe FDA has granted an Emergency Use Authorization (EUA) which enables the treatment of COVID-19 in hospitalized adult and pediatric
Read moreAleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a partnership to advance the early phase clinical development of Aleta’s
Read moreKite, a Gilead Company, and Shoreline Biosciences have announced a $2.3 Billion strategic partnership to develop novel cell therapies across
Read moreThe legal dispute between the British-Swedish biopharmaceutical giant AstraZeneca and the European Union over a contract to deliver COVID-19 vaccines
Read moreSingle-step purification and optimized reaction chemistry enable SARS-CoV-2 PCRwithin ~70 minutes. A BioEcho Life Sciences Case Study Laboratory-based polymerase chain
Read moreSARS-CoV-2 PCR’s Without RNA Extraction With the CE-IVD approved Volcano3G® Direct COVID-19 Kit diagnostic labs can completely skip the time-consuming
Read moreThe Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of the Pfizer-BioNTech vaccine in children aged 12-15
Read moreDanish multinational pharmaceutical company Novo Nordisk and Japanese cardiac regenerative medicine specialist Heartseed have confirmed an exclusive global partnership and license
Read more